Tormey D C, Falkson G, Crowley J, Falkson H C, Voelkel J, Davis T E
Am J Clin Oncol. 1982 Feb;5(1):33-9.
The therapeutic effectiveness of combining tamoxifen with a combination chemotherapy regimen was tested in 135 patients with advanced breast cancer previously treated with chemotherapy. Patients were randomly allocated to received dibromodulcitol + Adriamycin (DA, 55 patients) or DA + tamoxifen (DAT, 67 patients). An additional 13 patients less than 50 years of age were assigned to DAT (DATN). Pretreatment characteristics were similar across both regimens. DAT and DATN yielded similar results in the less than 50-year-old cohort. DAT tended to be superior to DA with respect to response rate (55% versus 36%, p = 0.004), time to treatment failure (medians: 170 days versus 110 days, log rank p = 0.001), responders' time to treatment failure (360 days versus 220 days, p = 0.035), and survival (340 days versus 270 days, p = 0.18). Toxicity was similar in both regimens. Thus, addition of tamoxifen to a second-line DA regimen appears to increase the therapeutic effectiveness. It is suggested that the addition of this antiestrogen to other chemotherapy regimens would also be beneficial.
在135例先前接受过化疗的晚期乳腺癌患者中，对他莫昔芬联合化疗方案的治疗效果进行了测试。患者被随机分配接受二溴卫矛醇+阿霉素（DA，55例患者）或DA+他莫昔芬（DAT，67例患者）。另外13例年龄小于50岁的患者被分配至DAT组（DATN）。两种治疗方案的预处理特征相似。在年龄小于50岁的队列中，DAT和DATN产生了相似的结果。在缓解率方面（55%对36%，p = 0.004）、至治疗失败时间（中位数：170天对110天，对数秩检验p = 0.001）、缓解者至治疗失败时间（360天对220天，p = 0.035）以及生存率（340天对270天，p = 0.18）方面，DAT倾向于优于DA。两种治疗方案的毒性相似。因此，在二线DA方案中添加他莫昔芬似乎可提高治疗效果。有人提出，在其他化疗方案中添加这种抗雌激素药物也将是有益的。
